Chronic skin wounds represent a significant clinical burden, especially in diabetic patients whose skin wounds can become ulcerated and even lead to limb amputation. The current state of the art in biologic drugs for improving wound healing is Johnson and Johnson's Regranex®, one of the only clinically effective biologic drugs, which delivers platelet-derived growth factor significantly improving wound healing, but unfortunately cannot close 50% of chronic wounds [1] . Recently, small interfering RNA (siRNA) has been proposed as a potential treatment for a range of pathologies including skin wounds, and biomaterial scaffold-based siRNA delivery has been recently sought using both natural and synthetic scaffolds [2] [3] [4] [5] .
Non-healing diabetic skin wounds are characterized by a heightened and unresolved inflammatory phase leading to chronic ulceration. Because specific inflammatory mediators integral to this phenotype have been identified, siRNA may be a strong candidate drug for the treatment of chronically inflamed ulcers through sequence-specific gene silencing. By silencing pro-inflammatory genes (for example, p53, and Smad3 silencing have previously been attempted to improve wound healing) [4, 5] the wound site may be transformed into a more reparative environment that enables progression from the prolonged inflammatory phase and into remodeling and wound closure.
siRNA Discovery and Mechanism
Controlled manipulation of gene expression using RNA interference (RNAi) has been rigorously pursued for almost two decades now, and thorough elucidation of this mechanism combined with recent breakthroughs in RNA delivery technologies have RNAi poised to make a tremendous impact. The initial discovery of RNAi came in 1990 when Napoli et al. observed an unexpected reduction in expression when delivering RNA in an attempt to overexpress chalcone synthase in Petunias [6] . Others elucidated and applied this finding by delivering antisense oligodeoxynucleotides (ODN), complementary sequences of DNA, which yielded modest reduction in gene expression in C. elegans [7] . In 1998, Fire et al. showed that intracellular-acting double stranded RNA (dsRNA) was more effective than either the sense or anti-sense strand alone [8] . In fact, dsRNA has been shown to be 100 to 1000 times more effective than ODNs due to a longer half-life and greater potency [9] . Over the next few years, researchers proved that endogenous RNAi, known as microRNA (miRNA), exist and that it serves as a natural, post-transcriptional controller of gene expression where cellular machinery selectively degrades complementary mRNA in an enzymatic manner [10] . The elucidation of similar machinery for RNAi in mammalian cells further heightened the interest in therapeutically harnessing these pathways [11] .
Since these early findings, the mechanisms of ODN and that of miRNA, dsRNA, siRNA, and short hairpin RNA (shRNA) have been more clearly elucidated (see Fig. 1 ). Single-stranded antisense ODN are thought to function by multiple mechanisms including translational arrest due to steric blockage of ribosomes by ODN-mRNA Watson-Crick base pairing and also through RNase-Hmediated cleavage of both the ODN and mRNA strands [12] . Endogenous RNAi molecules in the form of microRNA (miRNA) enter the cytoplasm after transcription, or alternatively, functionally-similar dsRNA can be exogenously delivered. shRNA that more closely mimic the structure of endogenous miRNA have also been exogenously delivered [13] . In each of these cases, the RNase III family enzyme Dicer cleaves the miRNA/dsRNA/shRNA to produce guide RNA, more commonly known as small interfering RNA (siRNA). siRNA are double-stranded RNA 19-21 base pairs in length with 3' nucleotide overhangs [14] , these molecules can assemble into the RNA induced silencing complex (RISC), a nuclease complex that degrades complementary mRNA in a sequence specific, enzymatic manner [10] . RNAi efficiency has been further improved by delivering siRNA that directly enters the RISC rather than upstream dsRNA/shRNA that must be processed first by Dicer [15] .
These favorable properties of siRNA have led to rapid advancement into clinical tests for a variety of conditions including respiratory syncytial virus infection, macular degeneration, hepatitis B, renal failure, macular oedema, pachyonychia congenital, and solid tumors [16] [17] [18] .
Figure 1 -RNAi mechanism:
Mechanisms of RNA Interference (A) ODN silencing is believed to be induced by stericly blocking translation through hybridization with mRNA and RNAse-H mediated degradation of both the ODN and mRNA (B) Proposed mechanisms for RNA interference by miRNA, shRNA, dsRNA, and siRNA. Endogenous miRNA, which is made transcriptionally, and exogenously delivered shRNA/dsRNA must all be first processed into siRNA, double stranded RNA molecules around 20 base pairs in size. Exogenous siRNA can also be delivered that circumvents the need for dicer processing. siRNA is loaded onto the RISC complex and mediates degradation of mRNA complementary to the antisense siRNA strand. For each type of therapeutic RNAi, the exogenous RNA must reach the cytoplasm to interact with mRNA and other intracellular machinery required for gene silencing.
Smart Delivery
siRNA is regarded to have untapped clinical potential, but one of the major challenges to harnessing RNA interference pharmaceutically is efficient cytoplasmic delivery of the siRNA biomacromolecules into target cells. "Naked" siRNA has a very short half-life in vivo due to rapid degradation by nucleases and clearance through kidney filtration. siRNA is also relatively large molecular weight, anionic, and polar, making it impermeable to cell membranes. This is problematic for initial cellular internalization and for escape from endo-lysosomal vesicles following uptake by endocytosis. Thus, siRNA carriers are required that can both package and protect the siRNA and deliver siRNA into the cytoplasm of the cell where the RISC machinery is located. Polycations have been heavily studied as an approach to package and protect siRNA and enable endosome escape via the proton sponge effect. However, most polycations are characterized by cytotoxicity and instability in vivo, and recent efforts have aimed to overcome these limitations.
Sustained Delivery
Although siRNA activity is catalytic, it does have a finite half-life in the cell. Previous reports generally note maximum silencing at around two days post-transfection [19] with normal gene expression restored by approximately one week in rapidly dividing cells [20] . One approach to extend silencing may be to achieve sustained, local release from scaffolds injected or transplanted onto the wound. Mostly natural materials such as alginate, collagen, and agarose have been pursued for biomaterial-based siRNA delivery to this point [2] [3] [4] [5] . Recently, key proof-of-concept studies were published describing effective topical siRNA gene silencing in vivo using agarose scaffolds loaded with siRNA packaged into the commercial transfection reagent Lipofectamine 2000. This particular approach represents a significant breakthrough, though it did suffer from the potential limitation of siRNA diffusing from the scaffold in a relatively rapid "burst" release that required removal and reapplication of siRNA-loaded scaffolds to achieve better and more sustained siRNA activity [4, 5] . It may be possible to achieve more optimal wound therapies with delivery systems that integrate efficient, nontoxic siRNA carriers into an injectable delivery matrix that can achieve sustained and tunable rates of siRNA release for greater than 1 week. advanced into clinical trials for indications such as macular degeneration [21] , skin disorders [22] , and targeted delivery to melanoma [18, 23, 24] . The current work focuses on development of a platform technology to be used for the controlled, local delivery for regenerative medicine, which is a less mature but promising application area for siRNA [25] .
Effective delivery has been the primary limitation to more rapid and widespread adoption of siRNA for clinical use due to its susceptibility to nucleases and poor intracellular cytosolic delivery [26] . A variety of strategies have been developed to protect siRNA and improve intracellular delivery including electrostatic complexation with cationic lipids, polymers, and polysacaccharides, as well as conjugation to cell-penetrating/fusogenic peptides, dendrimers, antibodies, vitamins, and nanoparticles [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] . Controlled polymerization techniques such as reversible addition-fragmentation chain transfer (RAFT) polymerization offer a promising approach to designing synthetic polymers that are monodispersed, and contain spatially-defined functionalities [38, 39] , and the current work employs a RAFT-synthesized, pH-responsive polymer-based micellar nanoparticle (si-NP) recently optimized for efficient and biocompatible intracellular siRNA delivery [40, 41] .
The polyplex, bioconjugate, and nanoparticulate siRNA carriers that have advanced to in vivo preclinical testing have been primarily delivered intravenously or through local injection (i.e., intratumoral) in PBS. For tissue regeneration applications, it is anticipated that it will be desirable for siRNA activity to be locally sustained and mediated from a biocompatible and biodegradable tissue template. Because siRNA activity is typically transient and can be exhausted by one week in rapidly dividing cells [19, 20] , natural materials including alginate, collagen and agarose have been applied for sustained delivery of siRNA [2] [3] [4] [5] . Pre-fabricated synthetic scaffolds made from ε-caprolactone and ethyl ethylene phosphate copolymer (PCLEEP) nanofibers have also been pursued for the release of siRNA/transfection reagent (TransIT-TKO) complexes and have been shown to achieve sustained delivery of bioactive siRNA for 28 days [42] .
Porous, biocompatible, and biodegradable polyester polyurethanes (PUR) comprise a promising class of synthetic injectable biomaterials that can provide both mechanical support and also controlled drug release to regenerating tissues [43] . Several drugs, including insulin-like growth factor-1 (IGF-1), hepatocyte growth factor (HGF), basic fibroblast growth factor (bFGF), recombinant human bone morphogenetic protein 2 (rhBMP-2), platelet-derived growth factor (PDGF), and the antibiotic vancomycin have been incorporated into and delivered from PUR scaffolds [44] [45] [46] [47] [48] .
Additionally, PURs support the ingrowth of cells in excisional cutaneous wounds [47] and bone defects [46, 48] . Further advantages of PURs are that they adhere to tissue, do not stimulate inflammation [47] , and biodegrade into biocompatible side products at rates that can be tuned based on the polyester triol and isocyanate precursor compositions [49] . Importantly, the use of lysinederived polyisocyanates in the PUR scaffolds makes them more clinically translatable because they can be synthesized using a two-component foaming process that allows a short manipulation time for filling of any shape or size defect, followed by rapid curing in situ [50, 51] .
The current study pursues a novel application of PURs to deliver pH-responsive micellar siNPs designed for the intracellular delivery of siRNA. This investigation validates homogenous loading of siRNA nanocarriers within the PUR scaffold, sustained, diffusion-controlled release of intact nanoparticles, and maintenance of gene silencing bioactivity of the released si-NPs.
Methods

Materials
All chemicals were purchased from Sigma-Aldrich (Milwaukee, WI, USA) except the following. Purchase of siRNA was from Applied Biosciences (Ambion), LDH cytotoxicity kit from Roche, Hiperfect transfection reagent (positive control) from Qiagen, and PD10 desalting columns from GE healthcare. Lysine Triisocyanate (LTI) was purchased from Kyowa Hakko Kogyo Co., Ltd.
(Tokyo, Japan). DMAEMA, and butyl methacrylate were vacuum distilled prior to use. 2,2'-Azobis(2-methylpropionitrile) (AIBN) was recrystallized twice with methanol.
Synthesis of 4-cyano-4-(ethylsulfanylthiocarbonyl) sulfanylvpentanoic acid (ECT)
The RAFT chain transfer agent ECT was synthesized following protocols previously described by Convertine et al. [40] adapted from Moad et al. [52] . 
Synthesis of 2-propyl acrylic acid (PAA)
The synthesis of PAA was adapted from existing methods [53] . In brief, diethyl propylmalonate (200 mmol, 40.45 g) was stirred in 1M KOH in 95% ethanol and acifidied with HCl to yield 2-carbopropoxybutyric acid, which was reacted with diethylamine (200 mmol, 14.62 g) and formalin (200 mmol, 16.11 g) at room temperature for 24h, followed by reflux at 60°C for 8 hours.
After acidification, the resulting 2 propylacrylate was refluxed in 2M KOH for 20 h to yield 2-propyl acrylic acid, which was extracted, dried, and vacuum distilled under vacuum to yield a colorless oil. 1 Synthesis and characterization of pDMAEMA macro CTA
The synthesis of the poly[2-(diethylamino)ethyl methacrylate] pDMAEMA macro chain transfer agent (mCTA) was conducted by RAFT polymerization using conditions adapted from [40] .
Based on a polymerization kinetics experiments (Appendix A), the RAFT polymerization was conducted at 70 °C under a nitrogen atmosphere for eight hours with 1,4-dioxane as the solvent (70% by weight), an initial monomer to CTA ratio of 100, and a CTA to initiator ratio of 10. The pDMAEMA mCTA was isolated by precipitation into n-hexane (x3) and dried overnight. The polymer was analyzed by gel permeation chromatography (GPC, Shimadzu Crop., Kyoto, Japan) with an inline Wyatt miniDAWN TREOS light scattering detector (Wyatt Technology Corp., Santa Barabara, CA) and 1 H nuclear magnetic resonance spectroscopy (NMR, Bruker 400Mhz Spectrometer equipped with 9.4 Tesla Oxford magnet) for molecular weight and polydispersity.
Synthesis and characterization of DMAEMA-b-(PAA-co-BMA-co-DMAEMA)
RAFT polymerization was utilized to synthesize the second block as previously described [40] . Additional monomers butyl methacrylate (BMA), PAA, and DMAEMA were added to the pDMAEMA mCTA chain with an initial monomer to mCTA ratio of 250 in stoichiometric quantities of 50% BMA, 25% PAA, and 25% DMAEMA. The initiator AIBN was used with a mCTA to initiator ratio Cytotoxicity NIH3T3 cells were seeded at a density of 12,500 cells/cm 2 in a 96 well plate and allowed to adhere overnight. si-NPs were then added in fresh media and allowed to incubate for 24 hours. The cells were then lysed and analyzed for intracellular LDH with a Cytotoxicity Detection Kit (Roche Applied Science) as previously described [57] , and a plate reader (infinite F500, Tecan Group Ltd., Mannedorf, Switzerland) set for absorbance at 492nm with reference at 595nm.
Statistical analysis
All data are reported as means ± standard error of the mean (SEM). Analysis of Variance (ANOVA) was used to determine treatment effects and p<0.05 was considered significant.
Results
Polymer synthesis and characterization 4-cyano-4-(ethylsulfanylthiocarbonyl) sulfanylvpentanoic acid (ECT) was synthesized as previously described [40] . 2-propyl acrylic acid (PAA) was synthesized using established methods [53] . RAFT polymerization was used to synthesize a mCTA of DMAEMA (M n = 11200g/mol, PDI = Chemical structure of the micelle-forming, pH-responsive diblock copolymer used for siRNA packaging and intracellular delivery. The homo-DMAEMA first block was designed for siRNA condensation due to the positive charge on the tertiary amines. The second block is pHresponsive and tuned for endosomal escape due to micelle destabilization and endosomolytic activity triggered by protonation of PAA and DMAEMA. B) Chemical structure of polyurethane precursors. LTI reacts with the -OH groups of the polyol to form urethane bonds and create the PUR network.
si-NP synthesis and characterization
Micellar nanoparticles were self-assembled in an aqueous environment and characterized for size and morphology by DLS and TEM respectively. TEM and DLS (Fig 3) report similar diameters of 31 nm and 39.6 nm respectively, with the smaller diameter seen with TEM being due to micelle dehydration. on a DLS-detected loss of micelle stability (Fig 4a) . DLS was also used to demonstrate the dependency of the CMC on pH. The results confirm that micelle structure was destabilized at pH 5 at a concentration of 100 g/mL, which is important for micelle endosomolytic behavior (Fig 4b) [41] . si-NP-loaded PUR scaffolds PUR foams were synthesized by reacting polyester triols (polyol) with lysine triisocyanate forming the porous polyurethane foam (Fig 2b) . Differential interference contrast microscopy (DIC) of PUR scaffolds revealed an intact, connected porous structure (Figure 5b,e) with a mean pore diameter of 150μm ± 64μm. Confocal microscopy shows a relatively homogenous distribution of fluorescently labeled siRNA containing NPs throughout the PUR matrix (Fig 5a-c) comparable to the distribution seen in the PUR containing naked siRNA (Fig 5d-f) . 
siRNA-NP Release Kinetics and Modeling
Release from the scaffold was quantitatively assessed using si-NPs made with fluorescently labeled siRNA. Approximately 20% of the payload was released in the first 12 hours followed by a sustained release approaching 80% cumulative release by 21 days (Fig 6) .
Figure 6 -Release of siRNA and si-NPs from PUR scaffolds is diffusion controlled:
The Weibull empirical model equation best-fit was determined and is overlaid here for each data set. Naked siRNA is rapidly released with an initial burst of over 60% at 12 hours and is entirely released by 3 days. si-NPs have a slower rate of release with a burst release of less than 20% during the first 12 hours, followed by sustained release that approaches 80% by 21 days.
Conversely, the much smaller naked siRNA diffuses from the scaffold much faster than si-NPs, reaching nearly 100% in 3 days. Importantly, TEM and DLS of releasate demonstrated that intact siNPs, although of larger diameter than fresh si-NPs (approximately 100nm), were delivered from the PUR scaffolds (Fig 2) .
The Weibull function has been previously used to evaluate the drug release mechanisms of drug eluting matrices that efficiently release their payload (cumulative release exceeding 60%) [48, 56] . The release of si-NPs was fit to the Weibull empirical model in Equation 1:
where M t is the mass of si-NPs released at time t, M ∞ is the total mass of si-NPs, a is a constant based on the system, and b is a constant based on the release kinetics. Previous reports suggest that values of b < 0.75 indicate that Fickian diffusion is the dominant release mechanism [48, 56] .
The values obtained from the best fit were found to be a=1.892, b=0.699, R 2 =0.995 for siRNA only and a=0.317, b=0.560, with R 2 = .996 for si-NPs.
For additional evidence supporting diffusion-controlled release of siRNA, we performed a scaling analysis to compare the predicted and measured initial release rates. The Stokes-Einstein equation (eqn 2) and the Higuchi equation [58] (eqn 3) were utilized together to further validate the diffusion-controlled release mechanism. These equations, where D is the diffusivity, M t is the rate of mass transfer, and r is the radius of the particle, provide relationships that allow the initial mass transfer rate to be related to the inverse of the square root of the radius of the solute:
√ Assuming all conditions except hydrodynamic diameter are maintained constant between the two samples except yields the following scaling prediction:
This analysis was completed assuming a hydrodynamic diameter of 2.56 nm for the siRNA, which was the value suggested by Barone et al for a 28 mer duplex RNA [59] . The hydrodynamic diameter of 38.69 nm that was experimentally determined using DLS for a charge ratio of 4/1 for siNPs was used. Based on the measured initial release of 17% for si-NPs and 66% for naked siRNA, the left side of Eqn. 4 reduces to 3.88 and the right side 3.87. Thus the scaling anlyais is consistent with the notion that the relase of siRNA from the scaffolds is governed by Fickaian diffusion.
PUR-released si-NP
Cytotoxicity experiments showed that the si-NPs were cytocompatible at the doses used (Appendix E). Gene expression analyzed by qRT-PCR showed significant reduction (p<0.05) in mRNA levels for GAPDH mediated by releasate collected between 0-24h, 24-48h, and 48-96h, while controls containing scrambled siRNA showed no activity (Fig 7a) . Further experimentation showed that PUR-released si-NPs produced dose dependent silencing of GAPDH expression with the highest dose of 50 nM producing approximately 50% gene knockdown (Fig 7b) while freshly prepared si-NPs produced a dose dependent silencing with 83% reduction at 50nM. The finding that there was a strong correlation between dose and gene silencing, indicated a siRNA dependent effect, and importantly, scrambled siRNA controls had no observable activity. The microscopic observation of diffuse fluorescent siRNA in the cytoplasm of cultured cells confirmed the maintenance of endosomolytic behavior, cytoplasmic delivery, and bioactivity of the PUR-released si-NPs (Fig 7c) . 
Discussion
Technologies that enable the efficient and sustained delivery of siRNA are a high-impact but relatively unmet need. This is primarily due to the number and complexity of the delivery barriers that exist. Here, a new platform is presented that is capable of both sustained and effective delivery of siRNA from a PUR scaffold capable of providing a biocompatible and biodegradable tissue template that can be cured in situ using a clinically-translatable injectable formulation. Due to nuclease susceptibility and membrane impermeability of naked siRNA, little success has been found with carrier-free siRNA delivery methodologies, and thus, the siRNA was first loaded into the pHresponsive micellar si-NPs prior to formulation with the biomaterial matrix.
The RAFT synthesized polymer shown in Fig 2A is the basis for the si-NPs and was specifically designed for improved cytoplasmic uptake, siRNA protection, and endosome escape [40, 41] . Toxicity of typically-utilized polyplexes made with cationic polymers [60] and the limitations associated with inefficient bioactivity due to lysosomal degradation or extracellular clearance [61] motivated the development of the polymer. si-NPs are formulated at positive charge ratios (typically 4:1) providing a net positive charge which facilitates efficient cell uptake by most cell types [62, 63] .
Once in the endosome, decreasing pH destabilizes the micelle structure due to protonation of PAA and DMAEMA monomers and exposes the membrane-disruptive core [64] . The configuration of the second block ( Fig. 2A) is finely tuned to provide a sharp pH response at the desired pH by incorporating appropriate amounts of hydrophobic BMA [65] and pH responsive DMAEMA and PAA.
Fig 4B confirmed the pH-dependent micelle destabilization using DLS and it is hypothesized that this destabilization allows the hydrophobic 2 nd block to penetrate and disrupt endosomal membranes and facilitate siRNA delivery to the cytoplasm [66] [67] [68] [69] . Once internalized, siRNA may be competitively dissociated from the polymer through interactions within the cytoplasm by other ionic molecules [62] thus gaining access to the RNAi machinery in the cytoplasm.
Recently, biomaterials have been pursued for sustained siRNA delivery, with natural materials such as alginate, collagen and agarose being mostly used in these applications due to their biocompatibility [2] [3] [4] [5] . However, these natural materials generally lack tunability and have been limited to rapid burst release of siRNA. The best sustained delivery to date has been achieved using PCLEEP nanofiber scaffolds, however, the manufacture of the scaffold requires complex equipment (electrospinning apparatus) and must be pre-made to a defined size and geometry [42] . Therefore, there still remains a significant need for a more clinically translatable biomaterial that can conform to tissue defects of varied sizes and shapes where it will cure in situ and deliver siRNA locally in a sustained manner.
PUR scaffolds provide multiple advantages as a biomaterial for controlled drug delivery to tissue defects for several reasons. PUR scaffolds can be easily adapted to be injectable making clinical use easier and requiring no additional fabrication equipment [50, 51] . After injection, PURs react in situ to form a biocompatible and biodegradable tissue scaffold with inter-connected pores that effectively serves as a template for cell influx and tissue formation and remodeling [47] . The mechanism of degradation includes hydrolytic degradation (on the order of months) and macrophagemediated oxidative degradation by reactive oxygen species (ROS) secretion (on the order of weeks)
that is ideal for the timescale of wound healing [49] . Finally, PUR has been shown to deliver biologics efficiently, typically delivering as much as 80% of the payload [46] [47] [48] . However, a previous study has reported that 50-m PLGA microspheres with rhPDGF bound to the surface supported <10% release over 21 days, suggesting that primary amines in the protein reacted with the polyisocyanate, resulting in loss of activity [47] . The present study has confirmed for the first time that nanoparticulate carriers incorporated in reactive PUR scaffolds support high-efficiency, diffusion-controlled release as seen in It is hypothesized that, in many applications, sustained delivery of siRNA into tissue defects will be ideal for producing a therapeutic effect since siRNA produces relatively transient gene silencing activity [70] . It is hypothesized that when the formulation tested here is translated in vivo, the initial burst release will establish gene silencing while the continual, slower siRNA delivery over the next few weeks will sustain the initial effect over a few weeks. Importantly, several approaches exist for tuning PUR-based drug delivery to be more rapid or more sustained [46] .
Fig 7A
demonstrates that the activity of released NPs is not significantly reduced over the time frames tested (0-24, 24-48, 48-96 hours). Sustained delivery of active complexes is critical to compensate for transiency of siRNA in a highly proliferative environment (i.e. tissue regeneration).
Fig 7B
demonstrates that the siRNA-mediated reduction in GAPDH of PUR-released si-NPs is dose dependent. However, it is evident that there is partial loss of bioactivity post-release from the scaffold compared to fresh si-NPs. It is possible that this reduction in silencing is due to reorganization of the micelle structure or a partial si-NP aggregation during lyophilization and incorporation into the PUR. There was a detectable difference in size revealed by TEM and DLS (Fig   3) of fresh micelles versus PUR-released micelles, and the potential of PUR-relesate si-NPs was also found to be reduced. It could also be possible that unreacted components in the PUR specifically adsorb to the surface of the released si--potential of the siNPs resulting in aggregation. Our unpublished data have shown that 1-2% of the PUR mass leaches from the reactive material during the first 45 minutes of cure when incubated in serum medium. The primary components in the leachates include polyester triol, dipropylene glycol, and triethylene diamine. Hydrolytic degradation of the cured scaffolds releases α-hydroxy acids [49] , which could bind electrostatically to the positive surface of the si-NPs. However, further studies will be necessary to better understand and overcome the alteration of the si-NPs during processing, and excipients such as agarose and sucrose may provide one route for improving their stability during lyophilization [71] .
Conclusions
Injectable poly(ester urethane) foams were successfully utilized for sustained release of bioactive si-NPs for an extended period of 21 days. The si-NPs synthesized using RAFT were found to remain intact and bioactive following incorporation into and release from PUR scaffolds, although changes in si-NP size and bioactivity were evident relative to fresh si-NPs. As a platform technology, the combination of PUR scaffolds and pH-responsive micellar siRNA carriers provides a logical approach to basic scientific studies of long-term siRNA-mediated gene silencing at local, pathological or healing tissue sites. The described system also has the potential to be applied to control cell phenotype and fate in tissue constructs developed in vitro. Finally, as a therapeutic, the described approach may be applied to reduce expression of deleterious genes and improve regeneration in tissue defects.
CHAPTER III FUTURE DEVELOPMENTS OF INTEREST
Optimization of Release
Based on the work presented in Chapter II, optimization of the quantity and quality of si-NPs is required. The mechanism of release from scaffold has been determined to be fickian diffusion, but details about the inclusion of si-NPs into the PUR scaffold are somewhat unclear. It is known that inclusion of PBS salts assists release. A better controlled system may utilize excipients that condense around si-NPs and covalently bind to the scaffold during synthesis [71] . These excipients may protect the structure, provide efficient release, and maintain their bioactivity. Encapsulation in PLGA microspheres may provide an additional method of controlling release [46] .
Further Degrees of Control
Adding additional functionality to the polymers may improve the activity upon release and may add provide an additional means of control. Methods of stabilizing the polymers through preparation may maintain activity. Moieties that assist in siRNA release may improve activity once present inside the cell. Also, on-demand release of active complexes could improve wound healing by releasing active si-NPs only when the wound environment is over-expressing inflammatory signals.
This may include a self-catalyzed hydrolytically degradable cation that can more efficiently unpacks and releases siRNA [72] . Reducible cationic polymers containing dithiols may have a similar effect by releasing siRNA when in the reducing environment of the cytoplasm in the presence of glutathione.
Micelle crosslinking provides a remarkable way of increasing the stability of micelles through the processing into PUR scaffolds and can provide an additional means of controlled release [73] . A pHresponsive cross-linked micelle would improve stability until delivered into endosomes where the pHlabile bonds would break. Similarly, reducible cross-linked micelles would only break apart once exposed to glutathione in the cytoplasm of cells making them more stable to delivery. Micelles may also be cross-linked with enzymatically degradable peptides. Lastly, micelles may be tethered to the scaffold through covalent linkages that are degradable by any of the aforementioned mechanisms (intracellular pH, reactive oxygen species signaling, enzymatic activity, etc) for on-demand release.
Finally, another potential future advance will be development of methods to achieve cell type-specific targeting of siRNA in the skin wound. For example, in hyperinflammatory wounds, one may be able to optimize therapeutic benefit and/or minimize nonspecific effects by targeting of siRNA specifically to leukocytic cell types.
Testing of siRNA targets in animal models Molecular biologists have made tremendous advances toward understanding the mechanistic control of wound healing. This body of work will help to identify a variety of genes whose silencing could be potentially sought in wound healing therapies. One future requirement will be to identify the most therapeutically useful target genes for different pathological situations (i.e, chronic wound vs.
burn or trauma victim, etc.). The first animal model tested will be a mouse that constituitivly expresses luciferase such that longitudinal gene knockdown studies can be done in the same mouse.
Next, reporter mice will be used that express luciferase upon stimulation through an NFκB promoter. 
